About Eisbach Bio
Eisbach develops novel drugs that disrupt molecular machines essential to tumors with defined genetic vulnerabilities in the context of DNA damage and repair (DDR). Its proprietary platform creates targeted therapies that exploit disease-relevant vulnerabilities. By shutting off the machine’s engine using allosteric inhibitors, Eisbach’s medicines are designed to prevent the reorganization and evolution of cancer genomes. Founded in 2019, Eisbach is privately held and backed by international investors.
- Founding: 2019
- Focus : Manufacturer
- Employees: 1-10
- Industry : Biotechnology, Pharma
News about Eisbach Bio
10-Nov-2021 | business & finance
Development of targeted SARS-CoV-2 antivirals
Eisbach Bio receives 6.7 million Euros grant from the Bavarian Government
10-Sep-2021 | research and development
Exploiting deep learning to develop sustainable COVID-19 inhibitors
Collaboration Eisbach Bio GmbH & Technische Universität Kaiserslautern
22-Jul-2021 | business & finance
Eisbach Bio receives EUR 8 million government grant to progress COVID-19 antiviral through Phase I/II clinical development
Eisbach Bio, a biotechnology company targeting the molecular machines that drive human disease, announced additional financial support from the German ...